91

subscribe

91 to partner with CCRM in commercializing regenerative medicine

91 announced today it has concluded an agreement with the Centre for Commercialization of Regenerative Medicine (CCRM) to provide 91-based startup companies with the benefit of CCRM’s market-leading business intelligence and experience.

Email address:
Published: 10 Mar 2021

$110M for Nine Innovative 91 Research Projects

Read the story in the 91 Reporter

Read the 91news release

Published: 9 Mar 2021

Marc Rousseau joins 91 as Director, Research Software

Research and Innovation and IT Services are pleased to welcome Marc Rousseau to the role of Director, Research Software / Directeur du Logiciel de Recherche. In this new role, Rousseau provides support and advice to the 91 research community on software, from grant applications to the implementation of research activities.

Published: 25 Feb 2021

Diamond Therapeutics Signs Agreement with 91 for Research on Low-Dose LSD

TORONTO,Feb. 4, 2021/CNW/ - Diamond Therapeutics Inc. ("Diamond"), a leading psychedelic drug development company focused on low-dose therapies for mental health, has entered into an agreement with91for the exclusive use of Dr.Gabriella Gobbi'sgroundbreaking studies with lysergic acid diethylamide (LSD), its mechanism of action on the brain, and its potential for use at low doses in the treatment of mental health disorders.

Published: 4 Feb 2021

Four 91 projects receive SSHRC Partnership Engage Grants

SSHRC invests over $80k in new 91 research projects through the Partnership Engage Grants competition, two of which are directly related to COVID-19 research.

Published: 28 Jan 2021

Major European grant backs 91 research on rare condition

The European Joint Programme on Rare Diseases (EJP RD) has granted 1.6 million euros in support of an international research collaboration specific to the ultra-rare genetic disease, Schinzel-Giedion Syndrome (SGS).

Published: 27 Jan 2021

91 team wins grant to study ‘trained immunity’ with Japanese researchers

Joint research program between the Japan Agency for Medical Research and Development and the Canadian Institutes of Health Research focuses on advancing technologies in epigenomics, deepening 91’s relationship with Japan’s RIKEN institute.

By Junji Nishihata

Published: 21 Dec 2020

Reminder: Canada Research Continuity Emergency Fund (CRCEF)

This is a reminder to all principal investigators to complete their Canada Research Continuity Emergency Fund Stage 3 claims as soon as possible.

Published: 10 Nov 2020

Kristina Öhrvall promoted to Assistant Vice-Principal, Research Development

Martha Crago, Vice-Principal, Research and Innovation, announced today that Kristina Öhrvall has been promoted to Assistant Vice-Principal, Research Development, for a five-year term.

Published: 9 Nov 2020

Research and Innovation on a summer schedule, starting June 26

Please note that Research and Innovation (R+I), including all of its associated units, will soon change to a summer schedule as per 91’s policy on Summer Fridays.

In practice, this means R+I will function with only minimal staff on Fridays throughout the summer, from June 26 until August 21. R+I will resume regular weekly office hours on Friday, August 28.

Published: 15 Jun 2020

Updates on Research Support during the Pandemic

Sent on behalf of Martha Crago, Vice-Principal (Research and Innovation)

Dear Colleagues,

I have been thinking of you often, as research is slowly ‎starting up again at 91.

Published: 15 Jun 2020

Call to 91 Researchers: Complete survey on COVID-19 Diagnostics R&D

The availability of reliable, rapid diagnostics is key to reopening our economies. Canada has an opportunity to take a leadership role in accelerating the development of these tests through a coordinated Canadian response. The goal is to support researchers to build networks and find collaborators/industry partners to advance their ideas to clinical trial and mass production. To that end, Dr.

Published: 29 May 2020

Help fight COVID-19 by joining the CanCOVID initiative

91 faculty with relevant expertise are encouraged to join the CanCOVID initiative, an expert community of Canadian COVID-19 researchers, clinical collaborators, and healthcare stakeholders.

Published: 17 Apr 2020

91 spinoff Laurent Pharmaceuticals to begin clinical trial on COVID-19 treatment

Company to run a Phase 2 clinical study with LAU-7b, a pro-resolving drug with potential antiviral properties against coronavirus

Published: 9 Apr 2020

Message to the 91 research community about CFI projects

On March 20, 2020, the Government of Quebec announced an immediate shutdown of constructions sites due to the COVID-19 pandemic. On April 7, it was announced that the date to resume construction activities isMay 4, 2020. This is a rapidly evolving situation and we will provide updated guidance and information as it becomes available.

Published: 6 Apr 2020

Pages

Back to top